Genpact (G) stock has drawn investor attention after recent trading left it down about 13% over the past month and roughly 24% over the past 3 months, prompting closer scrutiny of its current valuation.

Zooming out, Genpact’s recent weakness fits a longer period where momentum has faded. The 1 month share price return is down 13.41% and the year to date share price return is down 37.86%, while the 1 year total shareholder return is down 33.26%. This points to a shift in how the market is weighing its prospects and risks.

If this kind of pullback has you reassessing your watchlist, it can be useful to see what else is out there and scan 20 top founder-led companies

So with Genpact shares under pressure even as the business reports revenue of about US$5.2b and net income around US$569.6m, is the stock quietly slipping into undervalued territory or is the market already factoring in its future growth?

Most Popular Narrative: 33% Undervalued

Based on the most followed narrative, Genpact’s fair value estimate of $42.45 sits well above the last close at $28.53, which puts the current market weakness into sharper context.

Genpact's strong pipeline, particularly in high-growth verticals like high tech, manufacturing, and financial services, combined with increasing large-deal activity and stable operating leverage, is expected to support revenue and EPS growth in line with an improving operating margin profile and continued return of capital to shareholders.

Curious what earnings path, revenue mix shift, and margin profile line up with that fair value for Genpact, and how buybacks fit into the equation.

Result: Fair Value of $42.45 (UNDERVALUED)

However, Genpact still faces the risk that slower legacy BPO demand and tougher competition in AI led services could restrain revenue growth and pressure margins.

Next Steps

With mixed sentiment around Genpact at the moment, it helps to look past the headlines and weigh the underlying rewards and risks yourself. To see which positives investors are focusing on, review the 4 key rewards

Looking for more ideas beyond Genpact?

If Genpact has you reassessing your portfolio, this is a good moment to broaden your research with a few focused stock lists before the next move arrives.

• Target stability by scanning 71 resilient stocks with low risk scores to help cushion your portfolio when markets turn choppy.
• Hunt for value by checking out 44 high quality undervalued stocks that combine quality fundamentals with potentially lower market expectations.
• Spot future standouts early by reviewing screener containing 19 high quality undiscovered gems that many investors might not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.